A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
Status:
RECRUITING
Trial end date:
2026-07-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow).